Summary report – MenQuadfi®

Indication extension in Switzerland: 17 February 2026

Solution for injection for active immunisation against invasive meningococcal disease in children from 6 weeks of age and adults

The active substance in the vaccine MenQuadfi comprises polysaccharides of Neisseria meningitidis groups A, C, W-135 and Y which are bound to the tetanus toxoid carrier protein. MenQuadfi is available as a ready-to-use solution for injection in single doses.

MenQuadfi is a quadrivalent vaccine used for the prevention of (active immunisation against) invasive meningococcal disease caused by groups A, C, W and Y of the Neisseria meningitidis bacteria.

MenQuadfi was first authorised by Swissmedic on 5 October 2022 for active immunisation against invasive meningococcal disease in children from 12 months of age and adults.

The current indication extension means that MenQuadfi can now also be used for active immunisation against invasive meningococcal disease in children from as young as 6 weeks of age.

The indication extension for MenQuadfi was authorised as part of the joint initiative of the Access Consortium.

This joint initiative is a collaborative project between the drug regulatory authorities in Australia (Therapeutic Goods Administration, TGA), Canada (Health Canada, HC), Singapore (Health Sciences Authority, HSA), the United Kingdom (Medicines & Healthcare products Regulatory Agency, MHRA), and Swissmedic. The joint initiative coordinates the assessment of authorisation applications for preparations with new active substances and indication extensions for these preparations that have been submitted in at least two of the five countries.

The application for indication extension for MenQuadfi was submitted to the drug regulatory authorities in Australia (Therapeutic Goods Administration, TGA), Canada (Health Canada, HC), Singapore (Health Sciences Authority, HSA) and Switzerland. Each country assessed a part of the application and then shared and discussed the results. At the end of the process, each authority made its own, independent decision on whether to approve the indication extension.

Swissmedic considered the assessments of the foreign reference authorities in its decision.

The requirements for issuing a comprehensive SwissPAR (Swiss Public Assessment Report) and a Summary report on authorisation based on this SwissPAR have not been fulfilled. Swissmedic refers to the authorisation of the foreign reference authorities.

Further details of the Access joint initiative are published on the Swissmedic website: Access Consortium (swissmedic.ch).

Information for healthcare professionals:

MenQuadfi®

Healthcare professionals can answer any other questions.

• Printable version

^{This information is correct as at the date above. New information concerning the authorised medicinal product in question will not be incorporated into the Public Summary SwissPAR.}

^{Swissmedic monitors medicinal products authorised in Switzerland. Swissmedic initiates the necessary action in the event of newly discovered adverse drug reactions or other safety-relevant signals.}

^{New findings that could impair the quality, efficacy or safety of this medicinal product are recorded and published by Swissmedic. If necessary, the medicinal product information is adapted.}